Status: Recruiting
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Participants needed: 55
Trial details
Phase: Phase 2, Phase 3Age: 12-17Biological sex: AllType: InterventionalSponsor: CytokineticsUpdated: Apr 13, 2026Locations: 38
Eligibility criteria
Period 1: Treatment Period [+14]
Period 1: Treatment Period [+15]